Human 20S proteasome activity towards fluorogenic peptides of various chain lengths

References

Adams, J. (2002). Development of the proteasome inhibitor PS-341. Oncologist 7, 9–16.10.1634/theoncologist.7-1-9Suche in Google Scholar PubMed

Bogyo, M., Shin, S., McMaster, J.S., and Ploegh, H.L. (1998). Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 5, 307–320.10.1016/S1074-5521(98)90169-7Suche in Google Scholar

Ciechanover, A. (1998). The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17, 7151–7160.10.1093/emboj/17.24.7151Suche in Google Scholar PubMed PubMed Central

Coux, O. (1996). Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65, 801–847.10.1146/annurev.bi.65.070196.004101Suche in Google Scholar PubMed

Dolenc, I., Seemuller, E., and Baumeister, W. (1998). Decelerated degradation of short peptides by the 20S proteasome. FEBS Lett. 434, 357–361.10.1016/S0014-5793(98)01010-2Suche in Google Scholar

Elofsson, M., Splittgerber, U., Myung, J., Mohan, R., and Crews, C.M. (1999). Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′,β′-epoxyketones. Chem. Biol. 6, 811–822.10.1016/S1074-5521(99)80128-8Suche in Google Scholar PubMed

Glickman, M.H. and Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373–428.10.1152/physrev.00027.2001Suche in Google Scholar PubMed

Grigoreva, T.A., Tribulovich, V.G., Garabadzhiu, A.V., Melino, G., and Barlev, N.A. (2015). The 26S proteasome is a multifaceted target for anti-cancer therapies. Oncotarget 6, 24733–24749.10.18632/oncotarget.4619Suche in Google Scholar PubMed PubMed Central

Harris, J.L., Alper, P.B., Li, J., Rechsteiner, M., and Backes, B.J. (2001). Substrate specificity of the human proteasome. Chem. Biol. 8, 1131–1141.10.1016/S1074-5521(01)00080-1Suche in Google Scholar

Huang, X. and Dixit, V.M. (2016). Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 26, 484–498.10.1038/cr.2016.31Suche in Google Scholar PubMed PubMed Central

Kisselev, A.F. and Goldberg, A.L. (2005). Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 398, 364–378.10.1016/S0076-6879(05)98030-0Suche in Google Scholar PubMed

Kisselev, A.F., Garcia-Calvo, M., Overkleeft, H.S., Peterson, E., Pennington, M.W., Ploegh, H.L., Thornberry, N.A., and Goldberg, A.L. (2003). The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem. 278, 35869–35877.10.1074/jbc.M303725200Suche in Google Scholar PubMed

Kisselev, A.F., van der Linden, W.A., and Overkleeft, H.S. (2012). Proteasome inhibitors: an expanding army attacking a unique target. Chem. Biol. 19, 99–115.10.1016/j.chembiol.2012.01.003Suche in Google Scholar PubMed PubMed Central

Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Derno, S.D., Bennett, M.K., Van Leeuwen, F.W.B., Chanan-Khan, A.A., et al. (2007). Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna. Blood 110, 3281–3290.10.1182/blood-2007-01-065888Suche in Google Scholar PubMed PubMed Central

Kupperman, E., Lee, E.C., Cao, Y., Bannerman, B., Fitzgerald, M., Berger, A., Yu, J., Yang, Y., Hales, P., Bruzzese, F., et al. (2010). Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70, 1970–1980.10.1158/0008-5472.CAN-09-2766Suche in Google Scholar PubMed

Liggett, A., Crawford, L.J., Walker, B., Morris, T.C.M., and Irvine, A.E. (2010). Methods for measuring proteasome activity: current limitations and future developments. Leukemia Res. 34, 1403–1409.10.1016/j.leukres.2010.07.003Suche in Google Scholar PubMed

Maly, D.J., Leonetti, F., Backes, B.J., Dauber, D.S., Harris, J.L., Craik, C.S., and Ellman, J.A. (2002). Expedient solid-phase synthesis of fluorogenic protease substrates using the 7-amino-4-carbamoylmethylcoumarin (ACC) fluorophore. J. Org. Chem. 67, 910–915.10.1021/jo016140oSuche in Google Scholar PubMed

Nussbaum, A.K., Dick, T.P., Keilholz, W., Schirle, M., Stevanovic, S., Dietz, K., Heinemeyer, W., Groll, M., Wolf, D.H., Huber, R., et al. (1998). Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc. Natl. Acad. Sci. USA. 95, 12504–12509.10.1073/pnas.95.21.12504Suche in Google Scholar PubMed PubMed Central

Orlowski, M. and Wilk, S. (2000). Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch. Biochem. Biophys. 383, 1–16.10.1006/abbi.2000.2036Suche in Google Scholar PubMed

Poreba, M., Szalek, A., Kasperkiewicz, P., and Drag, M. (2014). Positional scanning substrate combinatorial library (PS-SCL) approach to define caspase substrate specificity. Methods Mol. Biol. 1133, 41–59.10.1007/978-1-4939-0357-3_2Suche in Google Scholar PubMed

Rawlings, N.D., Barrett, A.J., and Bateman, A. (2012). MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 40, D343–350.10.1093/nar/gkr987Suche in Google Scholar PubMed PubMed Central

Schwartz, A.L. and Ciechanover, A. (1999). The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 50, 57–74.10.1146/annurev.med.50.1.57Suche in Google Scholar PubMed

Voges, D., Zwickl, P., and Baumeister, W. (1999). The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015–1068.10.1146/annurev.biochem.68.1.1015Suche in Google Scholar PubMed